Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients

Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG‐degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single‐center, open‐label ascending‐dose study in highly sensitized patients with chronic kidney disease. Eight patients with cytotoxic PRAs (median cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorant, Tomas, Bengtsson, Mats, Eich, Torsten, Eriksson, Britt‐Marie, Winstedt, Lena, Järnum, Sofia, Stenberg, Yvonne, Robertson, Anna‐Karin, Mosén, Kristina, Björck, Lars, Bäckman, Lars, Larsson, Erik, Wood, Kathryn, Tufveson, Gunnar, Kjellman, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221156/
https://www.ncbi.nlm.nih.gov/pubmed/29561066
http://dx.doi.org/10.1111/ajt.14733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221156/
https://www.ncbi.nlm.nih.gov/pubmed/29561066
http://dx.doi.org/10.1111/ajt.14733

Ejemplares similares